What iRepertoire does

iRepertoire, Inc. is a privately held life-sciences company founded in 2009 and headquartered at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. The company focuses on immune repertoire sequencing for T-cell receptors (TCR) and B-cell receptors (BCR), serving biopharma discovery and clinical teams, academic immunologists, and clinical researchers working in immuno-oncology, autoimmune disease, infectious disease, cell therapy, and transplant immunology. Its commercial track record includes 190+ peer-reviewed publications since inception, 8,000+ sequenced hybridomas, and self-reported GCLP-compliant operations.

The technical foundation is a proprietary multiplex PCR chemistry — arm-PCR and dam-PCR — which the company describes as the only commercialized method capable of amplifying all seven immune receptor chains (TCR alpha, beta, gamma, delta and BCR heavy, light kappa, light lambda) in a single reaction. The product surface spans bulk repertoire sequencing (RepSeq+, RepSeq IQ), single-cell paired-chain sequencing (iPair, iPair+), shippable reagent kits (iR-Complete Dual Index Primer Kits), targeted immunophenotyping (ImmunoSight, 150+ genes), hybridoma sequencing services, and the Intellimune analytics platform incorporating edgeR-based differential analysis, CDR identification, and predictive antigen-specificity analytics. Output is supported by UMI-based error correction and integrated bioinformatic services.

Commercially, iRepertoire runs a hybrid revenue model combining project-based professional sequencing services (quote-based, multi-program engagements) with reagent kit product sales and an international distributor channel for select products. Go-to-market is sales-led, directed at biopharma pipeline teams and academic immunology groups, and supported by publications, case studies, webinars, conference presence, and a learning center. Self-disclosed customer reference points span unnamed biopharma programs, academic institutions, and research foundations including HudsonAlpha, ImmuneWatch, the Lupus Research Alliance, and the F. Champalimaud Foundation, indicating a diversified customer base with limited named-anchor revenue concentration.

Name

iRepertoire

Legal name

iRepertoire, Inc.

Website

https://irepertoire.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

iRepertoire is a privately held immune repertoire sequencing company founded in 2009 in Huntsville, Alabama, providing proprietary TCR/BCR sequencing services, single-cell kits, and bioinformatics to biopharma, academic, and clinical researchers in immuno-oncology, autoimmune, infectious disease, and cell therapy.

Ownership category

akta.pro rank

Product category

Immune Repertoire Sequencing Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Immune repertoire sequencing
• TCR BCR profiling
• Single-cell V(D)J
• Adaptive immune analysis
• Immunogenomics services

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Sequencing Services (RepSeq, RepSeq+): Full-service bulk immune repertoire sequencing including library preparation, Illumina sequencing, and basic data analysis. RepSeq+ offers enhanced sensitivity with UMI-based error correction for seven-chain analysis.
2. Single Cell Services (iPair, iPair+): Single-cell V(D)J sequencing services capturing physically paired TCR/BCR chains. Includes FACS sorting options, with iPair+ adding targeted gene expression phenotyping.
3. iR-Complete Kit Sales: Sale of reagent kits (12, 24, 48, or 96 reaction kits) for customer-run immune repertoire sequencing using proprietary arm-PCR technology with dual index labeling.
4. Data Analysis Services (Intellimune): Advanced bioinformatics and data interpretation services across multiple tiers (Core, Plus, Pro, Discovery) with expert scientific support for translating raw sequencing data into biological insights.
5. Hybridoma Sequencing: Sequencing service for hybridoma cell lines to characterize antibodies, with accompanying MonoVDJseq reagent kit for in-house library preparation.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

iRepertoire develops and commercializes immune repertoire sequencing technology, providing full-service adaptive immune receptor profiling (TCR/BCR) for biopharmaceutical companies, academic institutions, and clinical researchers. The company combines proprietary arm-PCR and dam-PCR multiplex PCR chemistries with NGS to deliver bulk sequencing, single-cell V(D)J, targeted immunophenotyping, and hybridoma antibody characterization services, supported by its Intellimune bioinformatics platform and reagent kits (iR-Complete) for customer-run workflows.

Product overview

iRepertoire offers a comprehensive suite of adaptive immune receptor profiling and data analysis solutions centered on TCR/BCR sequencing technology. The portfolio spans bulk sequencing services (RepSeq+ for 7-chain immune repertoire analysis, RepSeq IQ for quantitative gDNA sequencing), single-cell solutions (iPair for paired V(D)J sequencing, iPair+ with phenotypic gene expression), and targeted immunophenotyping (ImmunoSight for 150+ gene panels). The Intellimune data analysis platform provides scalable bioinformatics across three tiers (Core, Plus, Pro) for interpretation of AIRR data. Supporting offerings include Hybridoma Sequencing for antibody characterization, iR-Complete reagent kits for in-house processing, and sample processing/sequencing services. Core proprietary technologies include arm-PCR (Amplicon Rescue Multiplex PCR) for inclusive expressed repertoire capture and dam-PCR (Dimer Avoided Multiplex PCR) for quantitative analysis. The platform is designed for biomarker discovery and therapeutic development across immuno-oncology, autoimmune diseases, infectious diseases, and cell therapy optimization.

Differentiator

Problem solved

Functional benefit

Brands

• RepSeq+: Seven-chain adaptive immune repertoire profiling service with sensitive, quantitative, high-throughput assay combining multiplex PCR with NGS
• RepSeq IQ
• ImmunoSight
• iPair
• iPair+
• Intellimune
• arm-PCR
• dam-PCR
• iR-Complete
• Hybridoma Sequencing
• MonoVDJseq

Products and services

• RepSeq+ A bulk adaptive immune repertoire sequencing service combining proprietary dam-PCR multiplex PCR with NGS to analyze any combination of all seven TCR/BCR chains (TCRα, TCRβ, TCRγ, TCRδ, IgH, IgK, IgL) in a single reaction with UMI-based error correction. Designed for biopharmaceutical companies, academic institutions, and clinical researchers conducting biomarker discovery, therapy monitoring, and immune profiling studies.
• RepSeq IQ A quantitative gDNA-based TCR/BCR AIRR sequencing service that uses internal quantitative controls and housekeeping genes to translate NGS reads into absolute copy numbers and standardized clone frequencies across samples. Targeted at clinical research studies requiring reproducible, quantitative immune repertoire profiling from genomic DNA.
• iPair A single-cell V(D)J sequencing service that captures physically paired full-length V(D)J sequences from TCRs or BCRs from FACS-isolated single cells in the same reaction well, using low reaction volumes for cost-effective paired-chain sequencing at single-cell resolution with over 90% amplification and over 80% pairing success rates.
• iPair+ An enhanced single-cell immune phenotyping service that combines iPair's physically paired TCR/BCR V(D)J sequences with co-expression analysis of over 100 phenotypic genes, providing integrated multi-omic data for translational research and cell therapy programs.
• ImmunoSight A fully customizable targeted NGS assay service that quantifies expression of 150+ immunophenotype genes alongside AIRR sequence data at bulk or single-cell resolution, providing comprehensive immunophenotyping data for clinical development and drug discovery programs.
• Intellimune Data Analysis An AIRR data analysis platform offered in tiered service levels — Core for foundational repertoire characterization, Plus for high-resolution metrics and visualizations, Pro for advanced clonal dynamics, cohort-level insights, and antigen specificity prediction, and Discovery for expanded research workflows. Provided as a scalable bioinformatics service to translate raw sequencing data into biological insights.
• iR-Complete Dual Index Kits Proprietary arm-PCR-based immune profiling reagent kits with Illumina Dual Index labeling sold for in-house library preparation. Available in 12, 24, 48, or 96 reaction sizes with RNA (all 7 chains for human/mouse) and gDNA (TCR beta, BCR IgH) formats, including complimentary access to the iR-Web data analysis platform.
• Hybridoma Sequencing A sequencing service that digitizes antibody libraries from hybridoma cell lines using the MonoVDJseq optimized BCR library preparation kit, enabling recombinant antibody production, humanization, and IP validation with high-quality sequencing data. Over 8,000 hybridomas have been sequenced using the company's technology.
• Sample Processing Sample preparation services supporting bulk repertoire and single-cell sequencing projects, including cell thawing, staining, FACS sorting, plating, and nucleic acid extraction. Capable of isolating rare cell populations at frequencies as low as 0.001%.
• Sequencing Services Flexible Illumina-based sequencing services (MiSeq, NextSeq, NovaSeq) tailored to project requirements with various read depth options to optimize per-library sequencing costs for immune repertoire and other sequencing projects.

Quantifiable outcome

• Amplification success rate of over 90% with pairing success rate of over 80% with all-in-one mixes for iPair single-cell sequencing
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• HudsonAlpha Institute for BiotechnologycoreStrategic or Co-development PartneriRepertoire was founded by immunologists at the HudsonAlpha Institute for Biotechnology and maintains its headquarters on the HudsonAlpha campus. This founding partnership provides access to biotech ecosystem resources and ongoing collaborative research opportunities.
• Lupus Research AllianceminorStrategic or Co-development PartnerPartnership focused on autoimmune disease research, specifically lupus. Collaborates on understanding disease mechanisms and developing therapeutic approaches through immune repertoire analysis.
• F. Champalimaud FoundationminorStrategic or Co-development PartnerInternational research partnership with the Champalimaud Foundation in Portugal, supporting translational immunology research and immune repertoire studies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Adaptive Biotechnologies: Direct competitor offering immunoSEQ (immune repertoire sequencing) and clonoSEQ (clinical clonal surveillance). Overlaps directly with iRepertoire's TCR/BCR sequencing services for pharma and clinical research, though at a much larger commercial scale and with public-company capital access.
• 10x Genomics: Direct competitor in single-cell immune profiling via the Chromium platform with V(D)J chemistry. Competes with iRepertoire's iPair for single-cell TCR/BCR paired sequencing customers, but offers a broader single-cell multi-omics portfolio and substantially larger commercial reach.

Broad incumbents

• Illumina: Incumbent sequencing platform provider whose NGS instruments underpin iRepertoire's services and whose recent push into broader sequencing-based applications (including immune-related assays) creates both an enabling dependency and a potential competitive threat at the platform layer.
• Thermo Fisher Scientific: Broad life sciences tools and services provider with reagent kits, sequencing instruments, and CRO services that overlap with iRepertoire's kit and service offerings, though at much greater scale and as part of a vastly larger product portfolio.
• Becton, Dickinson and Company (BD): Large life sciences incumbent with flow cytometry (FACS), single-cell sorting, and reagent offerings that intersect with iRepertoire's sample processing and single-cell sequencing services, particularly for cell therapy and immunology customers.
• NeoGenomics Laboratories: Clinical oncology-focused laboratory services provider with growing immune profiling and MRD capabilities; partially overlaps with iRepertoire's clinical-trial-support immune monitoring services, though anchored in clinical rather than research workflows.

Emerging players

• Standard BioTools (formerly Fluidigm): Single-cell genomics and mass cytometry provider whose targeted workflows and instrumentation overlap with iRepertoire's single-cell and immunophenotyping offerings, particularly for translational immunology research customers.
• AbCellera Biologics: Antibody discovery platform company using immune repertoire and BCR sequencing approaches that overlap with iRepertoire's hybridoma and BCR profiling services for therapeutic antibody developers, though focused on downstream drug discovery rather than sequencing tools.
• Personalis: Genomics services company with immuno-oncology and minimal residual disease offerings that overlap with iRepertoire's clinical-research sequencing services, particularly for biopharma customers in oncology and immuno-oncology.
• ImmunoPrecise Antibodies: Antibody discovery and characterization services company whose hybridoma sequencing and BCR repertoire work overlaps with iRepertoire's Hybridoma Sequencing and MonoVDJseq offerings for therapeutic antibody developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/iRepertoire

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iRepertoire